Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL)

G. Palmieri, A. Morabito, A. Rea, R. Lauria, V. Montesarchio, E. Biondi, M. Caraglia, P. Tagliaferri, A. R. Blanco

Research output: Contribution to journalArticle

Abstract

Fifteen patients from a series of 37 consecutive patients with aggressive NHL who achieved a complete remission (CR) with first line chemotherapy were defined at high or high-intermediate risk of relapse according to International Prognostic Risk Index and were treated with αIFN as maintenance therapy for two years. After a median follow-up of 62 months only 3/15 patients (20%) relapsed and 2/15 (13.3%) died in the αIFN treated group, favourably comparing with the expected relapse and death rate in that setting; on the other hand 40.9% of 'low risk' patients from the same series, who did not receive αIFN, had relapsed. αIFN maintenance therapy appears to result in prolonged response duration and survival in patients with aggressive and prognostically unfavourable NHL.

Original languageEnglish
Pages (from-to)733-735
Number of pages3
JournalOncology Reports
Volume3
Issue number4
Publication statusPublished - 1996

    Fingerprint

Keywords

  • aggressive non-Hodgkin's lymphoma
  • alpha-interferon
  • prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Palmieri, G., Morabito, A., Rea, A., Lauria, R., Montesarchio, V., Biondi, E., Caraglia, M., Tagliaferri, P., & Blanco, A. R. (1996). Maintenance therapy with recombinant interferon alpha-2B (αIFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL). Oncology Reports, 3(4), 733-735.